经心尖主动脉瓣置换与外科主动脉瓣置换在高危人群中的亚组分析
该研究基于德国2014至2016年全国数据集,比较了19,016例孤立SAVR与6,432例TA-TAVR的院内结局。经协变量和倾向性调整后,TA-TAVR组卒中、急性肾损伤、出血和延长机械通气风险更低,但院内死亡率无显著差异;<75岁和低手术风险患者SAVR死亡率更低,慢性肾衰竭患者TA-TAVR更优。
要点
- TA-TAVR组院内并发症(卒中、AKI、出血、>48h机械通气)调整后风险低于SAVR。
- <75岁及EuroSCORE 4-9患者SAVR院内死亡率更低(倾向调整后)。
- 慢性肾衰竭患者TA-TAVR院内死亡率优于SAVR。
核心结论
- <75岁和低手术风险患者行SAVR的院内死亡率低于TA-TAVR。
- 慢性肾衰竭患者行TA-TAVR的院内死亡率低于SAVR。
- 全体患者中两种策略的院内死亡率无明确优势。
研究设计与样本
- 基于德国2014至2016年全国数据集,纳入19,016例孤立SAVR和6,432例TA-TAVR。
- 采用协变量调整和倾向性调整分析控制风险因素。
主要发现
- TA-TAVR患者更年长、合并症更多,logistic EuroSCORE为5.3 vs 17.0(P < .001)。
- 调整后TA-TAVR组卒中、急性肾损伤、相关出血和>48小时机械通气风险更低(均P < .001)。
- 全体患者院内死亡率无显著差异(caOR 1.13,P = .251;paOR 1.12,P = .309)。
- <75岁患者SAVR倾向调整OR 2.12(P = .001);EuroSCORE 4-9患者paOR 1.43(P = .041)。
- 慢性肾衰竭患者TA-TAVR的caOR 0.56(P = .039)。
关键数值与推荐
- <75岁患者SAVR的paOR 2.12(P = .001),倾向调整后支持SAVR。
- EuroSCORE 4-9患者SAVR的paOR 1.43(P = .041),倾向调整后支持SAVR。
- 慢性肾衰竭患者TA-TAVR的caOR 0.56(P = .039)。
- 女性患者SAVR的caOR 1.42(P = .030),仅协变量调整有差异。
临床怎么用
- 对于<75岁或EuroSCORE 4-9的患者,SAVR可能是更优选择。
- 慢性肾衰竭患者可优先考虑TA-TAVR以降低院内死亡风险。
- TA-TAVR虽并发症风险较低,但需结合患者年龄和手术风险个体化决策。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: If the transfemoral access is not feasible, a transapical access or surgical aortic valve replacement (SAVR) are alternatives for patients with aortic valve stenosis. OBJECTIVES: To identify patient groups who benefit from SAVR or transapical transcatheter aortic valve replacement (TA-TAVR), we compared in-hospital outcomes of patients in a nationwide dataset. METHODS: We identified 19,016 isolated SAVR and 6432 TA-TAVR performed in Germany from 2014 to 2016. We adjusted for risk factors using a covariate- and propensity-adjusted analysis. RESULTS: Patients undergoing TA-TAVR were older, had more comorbidities, and accordingly greater estimated operative risk (logistic European System for Cardiac Operative Risk Evaluation 5.3 vs 17.0, P < .001). However, adjusted risk for in-hospital complications such as stroke, acute kidney injury, relevant bleeding, and prolonged mechanical ventilation >48 hours was lower in patients undergoing TA-TAVR (all P < .001). When we compared in-hospital mortality of all patients undergoing either TA-TAVR or SAVR, neither treatment strategy had a clear advantage (covariate-adjusted odds ratio [caOR], 1.13, P = .251; propensity-adjusted OR [paOR], 1.12, P = .309). Two patient subgroups seem to benefit more from SAVR than TA-TAVR: patients <75 years (caOR, 1.29, P = .237; paOR, 2.12, P = .001) and those with European System for Cardiac Operative Risk Evaluation 4-9 (caOR, 1.32, P = .114; paOR, 1.43, P = .041). Female patients had a tendency toward lower risk for in-hospital mortality when undergoing SAVR (caOR, 1.42, P = .030). In patients with chronic renal failure, TA-TAVR was superior (caOR, 0.56, P = .039, P = .040). CONCLUSIONS: Patients <75 years and those at low operative risk who underwent SAVR had lower in-hospital mortality than those undergoing TA-TAVR. Patients with chronic renal failure who underwent TA-TAVR had lower in hospital mortality than those that underwent SAVR.
引用
- Stachon P, Kaier K, Oettinger V, et al. Transapical aortic valve replacement versus surgical aortic valve replacement: A subgroup analyses for at-risk populations. J Thorac Cardiovasc Surg. 2020. PMID: 32222407. doi:10.1016/j.jtcvs.2020.02.078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。